Sulfur In R Patents (Class 514/618)
-
Publication number: 20090149397Abstract: In one aspect, the present invention provides a composition and a kit comprising a combination of topoisomerase inhibitor and PARP inhibitor for treatment of cancer. In another aspect, the invention provides a method of treating cancer comprising administering to a subject a combination of topoisomerase inhibitor and PARP inhibitor. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase and a topoisomerase, as well as providing formulations and modes of administering such compositions.Type: ApplicationFiled: December 5, 2008Publication date: June 11, 2009Inventors: Valeria Ossovskaya, Charles Bradley, Barry Sherman
-
Publication number: 20090143445Abstract: This invention provides the compound having the structure wherein n is 1-10; X is C—R11 or N, wherein R11 is H, OH, SH, F, Cl, SO2R7, NO2, trifluoromethyl, methoxy, or CO—R7, wherein R7 is alkyl, alkenyl, alkynyl, C3-C8 cycloalkyl, or aryl; Z is R2 is H or NR3R4, wherein R3 and R4 are each independently H, C1-C6 alkyl, or C3-C8 cycloalkyl; R5 is OH or SH; and R6, R12, R13, and R14 are each independently H, OH, SH, F, Cl, SO2R15, NO2, trifluoromethyl, methoxy, or CO—R15 wherein R15 is alkyl, alkenyl, alkynyl, C3-C8 cycloalkyl, or aryl, or a salt of the compound, which is useful in the treatment of tumors.Type: ApplicationFiled: October 1, 2008Publication date: June 4, 2009Inventors: John S. Kovach, Francis Johnson
-
Publication number: 20090137594Abstract: The present invention relates to pentafluorosulphanyl-substituted compounds, methods for their production, medicaments containing such compounds and the use of such compounds for producing medicaments.Type: ApplicationFiled: May 17, 2006Publication date: May 28, 2009Applicant: Gruenenthal GmgHInventors: Robert Frank, Bernd Sundermann, Hans Schick
-
Publication number: 20090123545Abstract: Compositions are described that comprise a modafÊnil component that is a combination of the d- and l-enantiomers of modafinil and wherein the modafÊnil component is greater than 50% by weight d-modafÊnil for use in promoting or enhancing the state of wakefulness, alertness, and/or central nervous system stimulation in an individual.Type: ApplicationFiled: July 21, 2006Publication date: May 14, 2009Inventors: Eyal S. Ron, Neal M. Farber, Daniel E. Katzman, Elkan R. Gamzu
-
Publication number: 20090118215Abstract: A novel method for the preparation of a highly densified and at least partly, preferably fully or almost fully hydrated ceramic for use in the preparation of a pharmaceutical composition notably for controlled-release of one or more therapeutically, prophylactically and/or diagnostically active substance. The method involves a concomitant step of hydrating and densifying a bioresorbable and hydratable ceramic such as calcium sulphate. The invention also relates to compositions comprising such a highly densified ceramic. The pharmaceutical composition is useful for targeted and controlled local prolonged release of active substances, e.g. anti-cancer agents, whereby the spectrum and severity of side effects are minimized due to an optimized local concentration-time profile.Type: ApplicationFiled: March 14, 2007Publication date: May 7, 2009Applicant: Lidds ABInventors: Hans Lennernas, Niklas Axen
-
Publication number: 20090118290Abstract: The presently disclosed subject matter provides derivatives of non-steroidal anti-inflammatory drugs (NSAIDs) that are characterized by substantially reduced cyclooxygenase inhibiting activity, yet retain the ability to interact with and modulate the activities of other polypeptides such as the class of peroxisome proliferators-activated receptors (PPARs) and ?-secretase. Also provided are methods of using the derivatives to treat pathological disorders.Type: ApplicationFiled: January 5, 2009Publication date: May 7, 2009Inventors: Lawrence J. Marnett, Jeffery J. Prusakiewicz, Andrew S. Felts, Chuan Ji
-
Patent number: 7528172Abstract: Compositions and methods for improving recovery following general anesthesia are provided. The composition comprises an effective dose of modafinil. Modafinil has been shown to reduce the symptoms associated with post-operative general anesthesia, improving the recovery form anesthesia.Type: GrantFiled: October 2, 2003Date of Patent: May 5, 2009Assignee: The Cooper Health System, Inc.Inventors: Ghassem E. Larijani, Michael E. Goldberg
-
Publication number: 20090105309Abstract: Compounds of formula (I): and salts, solvates, and physiologically functional derivatives thereof, useful for the prophylaxis or treatment of a clinical condition for which a selective ?2-adrenoreceptor agonist is indicated, for example asthma or chronic obstructive pulmonary disease (COPD).Type: ApplicationFiled: October 20, 2004Publication date: April 23, 2009Applicant: GLAXO GROUP LIMITEDInventors: Philip Charles Box, Diane Mary Coe, Heather Hobbs
-
Publication number: 20090105346Abstract: The invention encompasses crystalline forms of armodafinil, processes for preparing the crystalline forms of armodafinil, pharmaceutical formulation thereof, and method of treating excessive sleepiness using the formulations of the invention.Type: ApplicationFiled: October 2, 2008Publication date: April 23, 2009Inventor: Alexandr Jegorov
-
Publication number: 20090099264Abstract: The present invention provides compounds of formula I which are inhibitors of cathepsin S and as such are useful in the prevention and treatment of cathepsin S dependent diseases and conditions including, but not limited to, chronic obstructive pulmonary disease (COPD) and pain.Type: ApplicationFiled: May 30, 2006Publication date: April 16, 2009Applicant: MERCK FROSST CANADA LTD.Inventors: Cameron Black, Jacques Yves Gauthier
-
Patent number: 7511175Abstract: The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.Type: GrantFiled: January 5, 2006Date of Patent: March 31, 2009Assignee: Abbott LaboratoriesInventors: Jyoti R. Patel, Qi Shuai, James T. Link, Jeffrey J. Rohde, Jurgen Dinges, Bryan K. Sorensen, Martin Winn, Hong Yong, Peer B. Jacobson, Michael E. Brune
-
Publication number: 20090082461Abstract: The present application describes deuterium-enriched modafinil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: August 22, 2008Publication date: March 26, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090082462Abstract: The present application describes deuterium-enriched amodafinil, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: September 18, 2008Publication date: March 26, 2009Applicant: PROTIA, LLCInventor: Anthony W. Czarnik
-
Publication number: 20090076158Abstract: The present application describes deuterium-enriched bicalutamide, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.Type: ApplicationFiled: September 5, 2008Publication date: March 19, 2009Applicant: PROTIA, LLCInventor: Anthony W Czarnik
-
Publication number: 20090054444Abstract: Compounds of Formula (I) wherein R1 is a cycloalkylsulphonyl group, or pharmaceutically acceptable salts thereof, are useful in the prophylactic and therapeutic treatment of hyperglycemia and diabetes.Type: ApplicationFiled: August 9, 2005Publication date: February 26, 2009Inventors: Matthew Colin Thor Fyfe, Vilasben Kanji Shah
-
Publication number: 20090042907Abstract: The present invention provides compounds of the structure: wherein the constituent members are defined herein, including pharmaceutical compositions thereof and methods of treating diseases therewith.Type: ApplicationFiled: June 20, 2008Publication date: February 12, 2009Applicants: Cephalon, Inc., Cephalon FranceInventors: Edward R. Bacon, Sankar Chatterjee, Mohamed Iqbal, Brigitte Lesur, Philippe Louvet
-
Publication number: 20090036420Abstract: The present invention relates to methods of treating CNS disorders with a compound of formula I wherein X, R1, R2, R3, R4, R5, R6, R7, and R8 are as defined in the specification and pharmaceutically acceptable acid addition salts thereof.Type: ApplicationFiled: July 28, 2008Publication date: February 5, 2009Inventors: Guido Galley, Katrin Groebke Zbinden, Roger Norcross, Henri Stalder
-
Publication number: 20090036462Abstract: Formulations are provided for parenteral administration of (amino substituted (e)-2,6-dialkoxystyryl 4-substituted benzylsulfones and the sodium and potassium salts thereof for the prevention and/or treatment of conditions mediated by abnormal cell proliferation. Composition for parenteral administration are provided which comprise an effective amount of compound of formula I or a compound of formula IIa and at least about 50% by weight of at least one water soluble polymer selected from the group consisting essentially of polyethylene glycol (PEG), poly-oxyethylene, poly-oxyethylene-poly-oxypropylene copolymers, polyglycerol, polyvinylalcohol, polyvinylpyrrolidone (PVP), polyvinylpyridine N-oxide, copolymer of vinylpyridine N-oxide and vinylpyridine.Type: ApplicationFiled: July 15, 2005Publication date: February 5, 2009Applicant: Onconova Therapeutics, Inc.Inventors: Stanley C. Bell, Albert Wong, Manoj Maniar
-
Publication number: 20090023781Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.Type: ApplicationFiled: December 1, 2005Publication date: January 22, 2009Applicant: Virobay, Inc.Inventor: Eduardo L. Setti
-
Publication number: 20090018143Abstract: The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions of compounds of Formula (A): wherein Ar, X, Y, R1, R2, R3, and q are as defined herein; and their use in the treatment of diseases, including treatment of sleepiness, promotion of wakefulness, treatment of Parkinson's disease, cerebral ischemia, stroke, sleep apneas, eating disorders, stimulation of appetite and weight gain, treatment of attention deficit hyperactivity disorder (“ADHD”), enhancing function in disorders associated with hypofunctionality of the cerebral cortex, including, but not limited to, depression, schizophrenia, fatigue, in particular, fatigue associated with neurologic disease, such as multiple sclerosis, chronic fatigue syndrome, and improvement of cognitive dysfunction.Type: ApplicationFiled: November 8, 2007Publication date: January 15, 2009Applicants: Cephalon, Inc., Cephalon FranceInventors: Brigitte Lesur, Philippe Louvet, Rabindranath Tripathy
-
Publication number: 20090018202Abstract: Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.Type: ApplicationFiled: February 1, 2005Publication date: January 15, 2009Applicant: Cephalon, Inc.Inventors: Magali Bourghol Hickey, Matthew Peterson, Orn Almarsson, Mark Oliveira
-
Publication number: 20090012153Abstract: The invention relates to novel compounds of formula (I): H2N—CH(R1)—CH2—S—S—CH2—CH(R2)—CONH—R5, wherein R1 is a hydrocarbon chain, phenyl or benzyl radical, methylene radical substituted by a 5 or 6 atom heterocycle; R2 is a phenyl or benzyl radical, a 5 or 6 atom aromatic heterocycle, methylene group substituted by a 5 or 6 atom heterocycle; R5 is a CH(R3)—COOR4 radical, wherein R3 is hydrogen, an OH or OR group, a saturated hydrocarbon group, a phenyl or benzyl radical and OR4 is hydrophile ester, or 5 or 6 membered heterocycle comprising several heteroatoms selected from a group consisting of nitrogen, sulphur and oxygen, with at least two nitrogene atoms, wherein said heterocycle is substitutable by an alkyl C1-C6, phenyl or benzyl radical.Type: ApplicationFiled: June 26, 2008Publication date: January 8, 2009Applicant: PharmaleadsInventors: Bernard Roques, Marie-Claude Fournie-Zaluski
-
Publication number: 20080318930Abstract: Sulfonyl derivatives of structural formula I are selective inhibitors of the 11?-hydroxysteroid dehydrogenase-1. The compounds are useful for the treatment of diabetes, such as noninsulin-dependent diabetes (NIDDM), hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome or Syndrome X, and other symptoms associated with NIDDM.Type: ApplicationFiled: August 3, 2005Publication date: December 25, 2008Inventors: Sherman T. Waddell, James M. Balkovec, Gina M. Santorelli, Aaron H. Leeman, Milana Meletic, Xin Gu
-
Publication number: 20080317843Abstract: The present invention is directed to compositions comprising a nanoparticulate modafinil compositions, or a salt(s), or an enantiomer(s), or a prodrug(s), or a polymorph(s) or derivative thereof, having improved bioavailability. The nanoparticulate modafinil composition formulation particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of dyssomnias, including but not limited to, narcolepsy, chronic fatigue, eating disorders, compulsive behaviors, ADHD, addictions, substance abuse, sleepiness, nervous system diseases, conditions, syndromes, and symptoms and related diseases, conditions, and symptoms.Type: ApplicationFiled: July 12, 2007Publication date: December 25, 2008Applicant: Elan Corporation plcInventors: Scott A. Jenkins, Gary Liversidge, David Manser
-
Publication number: 20080312329Abstract: Disclosed are selective inhibitors of matrix metalloproteinases represented by the following formula (I). wherein X is (CH2)nO, (CH2)nS, (CH2)nNR1, (CH2)n(CH2), or CH?CH, wherein n=0, 1, or 2; R and R1 are, independently, a substituted or unsubstitued alkyl, alkenyl, alkynyl, aryl, heteroaryl group, cycloalkyl, heterocycloalkyl, cycloalkenyl, or heterocycloalkenyl; and Z is NH or CH2; or a pharmaceutically acceptable salt thereof. Also disclosed are methods of making such compounds and methods of using such compounds to inhibit tumor progression and to treat diseases such as arthritis.Type: ApplicationFiled: March 21, 2005Publication date: December 18, 2008Applicant: SOUTHERN RESEARCH INSTITUTEInventor: Subramaniam Ananthan
-
Publication number: 20080287446Abstract: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.Type: ApplicationFiled: March 22, 2006Publication date: November 20, 2008Inventor: Craig J. Mossman
-
Publication number: 20080286205Abstract: A method for treating prostate related diseases in a subject, the method comprising i) optionally administering to subject an initial boost dose of one or more active substances and/or prodrugs, and ii) administering locally into the prostate a controlled release pharmaceutical composition comprising one or more active substances in a biodegradable ceramic carrier. The biodegradable hydrating ceramic may be selected from the group consisting of non-hydrated or hydrated calcium sulphate, calcium phosphate, calcium carbonate, calcium fluoride, calcium silicate, magnesium sulphate, magnesium phosphate, magnesium carbonate, magnesium fluoride, magnesium silicate, barium sulphate, barium phosphate, barium carbonate, barium fluoride, barium silicate, or mixtures thereof. In a specific embodiment, the biodegradable hydrating ceramic is non-hydrated or hydrated calcium sulphate.Type: ApplicationFiled: March 31, 2006Publication date: November 20, 2008Applicant: Lidds AbInventors: Hans Lennernas, Bo Lennernas, Jonas Hugosson, Niklas Axen
-
Patent number: 7449493Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.Type: GrantFiled: July 14, 2005Date of Patent: November 11, 2008Assignees: Bristol-Myers Squibb Pharmaceutical Company, Bristol-Myers Squibb Pharma CompanyInventors: Percy Carter, Robert Cherney
-
Publication number: 20080275017Abstract: Novel sulfenate derivatives and their bioconjugates for phototherapy of tumors and other lesions. The sulfenates of the present invention are designed to absorb low-energy ultraviolet, visible, or near-infrared (NIR) region of the electromagnetic spectrum. The phototherapeutic effect is caused by direct interaction of free radicals, the reactive intermediate produced upon photofragmentation of the sulfenate moiety, with the tissue of interest.Type: ApplicationFiled: July 15, 2008Publication date: November 6, 2008Inventors: Raghavan Rajagopalan, Gary L. Cantrell, Samuel I. Achilefu, Joseph E. Bugaj, Richard B. Dorshow
-
Patent number: 7446225Abstract: The invention relates to pentafluorosulfanylphenyl-substituted benzoylguanidines of the formula I: and a process for preparing a compound of the formula I and/or the pharmaceutically acceptable salts thereof.Type: GrantFiled: March 9, 2007Date of Patent: November 4, 2008Assignee: Sanofi-aventis Deutschland GmbHInventor: Heinz-Werner Kleeman
-
Publication number: 20080269283Abstract: Aryl sulfone compounds of formula I and II are described and have therapeutic utility, particularly in the treatment of diabetes, obesity and related conditions and disorders:Type: ApplicationFiled: June 27, 2008Publication date: October 30, 2008Inventors: Pingchen Fan, Hiroyuki Goto, Xiao He, Makoto Kukutani, Marc Labelle, Dustin L. McMinn, Jay P. Powers, Yosup Rew, Daqing Sun, Xuelei Yan
-
Publication number: 20080269282Abstract: This invention is directed to inhibitors of copper-containing amine oxidases (E.C.1.4.3.6) including semicarbazide-sensitive amine oxidase (SSAO; also known as vascular adhesion protein-1, VAP-I), and their therapeutic use in inflammatory diseases, diabetes and its associated complications, atherosclerosis, neurodegenerative diseases, obesity, hypertension and cancer.Type: ApplicationFiled: August 2, 2005Publication date: October 30, 2008Applicant: GENMEDICA THERAPEUTICS SLInventors: Luc Marti Clauzel, Silvia Garcia Vicente, Francesc Yraola Font, Miriam Royo Exposito, Fernando Albericio Palomera, Antonio Zorzano Olarte
-
Publication number: 20080234233Abstract: A medicament for preventive and/or therapeutic treatment of neurodegenerative diseases such as Alzheimer's disease or the like which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is {circle around (1)} a fused polycyclic heteroaryl group wherein the ring which binds directly to —CONH— group in the formula (I) is a benzene ring, {circle around (2)} unsubstituted thiazol-2-yl group, or {circle around (3)} unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented byType: ApplicationFiled: May 20, 2008Publication date: September 25, 2008Applicant: INSTITUTE OF MEDICINAL MOLECULAR DESIGN INC.Inventors: Susumu MUTO, Akiko ITAI
-
Publication number: 20080221216Abstract: The invention provides a method of reducing spasticity in a mammal involving administering modafinil or related compounds. The spasticity can be secondary to multiple sclerosis, spinal cord injury, stroke, brain injury, and other causes.Type: ApplicationFiled: March 9, 2007Publication date: September 11, 2008Applicant: The Board of Trustees of the University of ArkansasInventor: Edgar Garcia-Rill
-
Publication number: 20080207761Abstract: Compositions of modafinil and methods of treating neurologically related conditions with the administration of modafinil. Also compositions that include modafinil and one or more excipients such as diluents, disintegrants, binders and lubricants.Type: ApplicationFiled: April 24, 2008Publication date: August 28, 2008Applicant: Cephalon, Inc.Inventors: Craig S. Heacock, Alpha B. Parikh, Piyush R. Patel
-
Publication number: 20080194694Abstract: The present invention relates to compounds of the formula (I) or a tautomer or prodrug thereof, or a pharmaceutically acceptable salt of said compound, tautomer or prodrug, wherein: R1, R2, R3, R4 and R5 are each independently selected from H, halo, CN, CF3 and CONH2; compositions containing such compounds and the uses of such compounds as antiparasitic agents.Type: ApplicationFiled: February 8, 2008Publication date: August 14, 2008Applicant: PFIZER LIMITEDInventors: Stuart Nicholas Comlay, Joanne Clare Hannam, William Howson, Christelle Lauret, Yogesh Anil Sabnis
-
Publication number: 20080194693Abstract: The invention relates to compounds of the general formula (I) wherein Ar, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, W, a, b, m, n, o and p are as defined in claim 1, and to any enantiomers thereof. The active ingredients have advantageous pesticidal for controlling parasites in warm-blooded animals.Type: ApplicationFiled: June 9, 2005Publication date: August 14, 2008Applicant: NOVARTIS AGInventors: Noelle Gauvry, Pierre Ducray, Thomas Goebel, Ronald Kaminsky
-
Publication number: 20080187508Abstract: Methods for treating glomerular basement membrane disease such as Alport syndrome involving matrix metalloproteinase-12 are disclosed. Treatment may be affected, for example, by administering matrix metalloproteinase-12 inhibitors, by administering CCR2 receptor inhibitors, or by administering MCP-1 inhibitors. Matrix metalloproteinase formation is affected by the CCR2 receptor, which is stimulated by the MCP-1 chemokine.Type: ApplicationFiled: September 8, 2005Publication date: August 7, 2008Applicant: BOYS TOWN NATIONAL RESEARCH HOSPITALInventor: Dominic E. Cosgrove
-
Publication number: 20080181966Abstract: Pharmaceutical compositions comprising modafinil in the form of particles of defined size and methods for preparing same. The particle size of modafinil can have a significant effect on the potency and safety profile of the drug.Type: ApplicationFiled: April 1, 2008Publication date: July 31, 2008Applicant: Cephalon, Inc.Inventors: Craig Heacock, Alpa Parikh, Piyush Patel
-
Patent number: 7405323Abstract: Modafinil polymorphic forms of modafinil racemate, methods of preparation thereof, pharmaceutical compositions and methods of therapeutic treatment involving modafinil polymorphic forms.Type: GrantFiled: October 12, 2005Date of Patent: July 29, 2008Assignee: Cephalon FranceInventors: Véronique Broquaire, legal representative, Ludovic Broquaire, legal representative, Laurent Courvoisier, Gerard Coquerel, Franck Mallet, Michel Broquaire
-
Publication number: 20080171767Abstract: Compounds of the general formula (I); wherein the substituents are as defined in claim 1, are useful as fungicides.Type: ApplicationFiled: November 29, 2005Publication date: July 17, 2008Applicants: SYNGENTA CROP PROTECTION, INC., SYNGENTA LIMITEDInventors: Roger Salmon, David Philip Bacon, Ewan James Turner Chrystal, David William Langton, Andrew Jonathan Knee, Gordon Richard Munns, Laura Quaranta, Hans-Georg Brunner, Renaud Beaudegnies, Fredrik Cederbaum, Fiona Murphy Kessabi
-
Publication number: 20080171750Abstract: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on use of modafinil, optionally in combination with one or more other neurogenic agents, to stimulate or activate the formation of new nerve cells.Type: ApplicationFiled: January 10, 2008Publication date: July 17, 2008Applicant: BrainCells, Inc.Inventors: Carrolee Barlow, Todd A. Carter, Andrew Morse, Kai Treuner, Kym I. Lorrain
-
Publication number: 20080161404Abstract: The present invention relates to a method of treating a metastatic prostate cancer patient by administering to said patient an effective amount of a bicalutamide (4?-cyano-??,??,??-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide) containing formulation capable of delivering at least a mean steady state plasma level of (R)-bicalutamide enantiomer of 40 ?g/ml; and to bicalutamide containing products and formulations capable of delivering the at least mean steady state plasma level of (R)-bicalutamide enantiomer of 40 ?g/ml to a patient in need thereof.Type: ApplicationFiled: February 21, 2006Publication date: July 3, 2008Applicant: ASTRAZENECA ABInventors: Kevin Joseph Carroll, Thomas Meredydd Morris, Ian Derek Cockshott, Bo-Eric Persson, Paul Alfred Dickinson
-
Publication number: 20080153918Abstract: Polymorphic forms of modafinil racemate, methods of preparation thereof, pharmaceutical compositions and methods of therapeutic treatment involving modafinil polymorphic forms.Type: ApplicationFiled: December 14, 2007Publication date: June 26, 2008Applicant: Cephalon FranceInventors: Michel Broquaire, Veronique Broquaire, Laurent Courvoisier, Armand Frydman, Gerard Coquerel, Franck Mallet
-
Publication number: 20080139636Abstract: The invention provides adamantane derivatives of formula (I), a process for their preparation, pharmaceutical compositions containing them, a process for preparing the pharmaceutical compositions, and their use in therapy. In formula (I) D represents CH2 or CH2CH2, E represents C(O)NH or NHC(O) and R3 represents a group of formula (I).Type: ApplicationFiled: June 20, 2007Publication date: June 12, 2008Inventors: Lilian Alcaraz, Moya Caffrey, Mark Furber, Timothy Luker, Michael Mortimore, Austen Pimm, Philip Thorne, Paul Willis
-
Publication number: 20080138315Abstract: The present invention is directed to a method for inducing UGT1A1 isoform expression for treatment of a disease, disorder or adverse effect caused by an elevated serum concentration of an UGT1A1 substrate comprising the step of administering to a subject an effective amount of ritonavir. In particular, the present invention is directed to a method of treating unconjugated hyperbilirubinemia by UGT1A1 induction comprising the step of administering to a subject an effective amount of ritonavir.Type: ApplicationFiled: January 15, 2008Publication date: June 12, 2008Inventors: Dale J. Kempf, Richard J. Bertz, Jeffrey F. Waring
-
Patent number: 7385086Abstract: This invention provides compounds and methods for treating, with said compound, a mycobacterial infection by administering to an animal a pharmaceutical composition containing a compound having the formula R—SOn-Z-CO—Y, where R is an alkyl groups having 6-20 carbon atoms, unsaturated hydrocarbon groups having 6-20 carbon atoms, or alkyl groups having 6-20 carbon atoms interrupted by at least one aromatic ring; Z is —CH2—, —CH2CH2—, —NH—NH—, —O—, ——NH—, —O—NH—, —CH2—NH—, —CH2—O—, —NH—O—, —NH—CH2—, —O—CH2—, and —CH?CH—; Y is —NH2, —O—CH2—C6H5, —CO—CO—O—CH3, and —O—CH3; and n is 1 or 2. It has been discovered that these compounds treat microbially-based infections caused by corynebacteria, nocardiae, rhodococcus, and mycobacteria. These compounds may be used to treat mycobacterial cells, such as Mycobacteria tuberculosis, drug resistant M. tuberculosis, M. avium intracellulare, M. leprae, M. paratuberculosis, and pathogenic Mycobacteria sp.Type: GrantFiled: January 27, 2004Date of Patent: June 10, 2008Assignee: The Johns Hopkins University School of MedicineInventors: Craig A. Townsend, James D. Dick, Gary R. Pasternack, Francis P. Kuhajda, Nicole M. Parrish
-
Patent number: 7375138Abstract: Pentafluorosulfanylbenzoylguanidines of the formula I and II in which R1 to R4 have the meanings stated in the claims, are suitable as antiarrhythmic medicaments with a cardioprotective component for the prophylaxis of infarction and treatment of infarction and for the treatment of angina pectoris. They also inhibit preventively the pathophysiological processes associated with the development of ischemia-induced damage, especially in the triggering of ischemia-induced cardiac arrhythmias.Type: GrantFiled: May 5, 2003Date of Patent: May 20, 2008Assignee: Sanofi-Aventis Deutschland GmbHInventor: Heinz-Werner Kleemann
-
Patent number: 7361653Abstract: The present invention relates to a composition for noxious organisms-controlling agent having a synergistic effect and a method for using said composition, which comprises, as active ingredients thereof, one or more compounds selected from the phthalamide derivatives represented by general formula (I) being useful as an insecticide or acaricide and one or more compounds selected from the compounds having insecticidal, acaricidal or nematocidal activity: wherein R1, R2 and R3 may be the same or different and each represent hydrogen atom, C3-C6 cycloalkyl, -A1-Qp, etc., each of X and Y may be the same or different and represents hydrogen atom, halogen atom, etc., n is an integer of 1 to 4, m is an integer of 1 to 5, and each of Z1 and Z2 represents O or S.Type: GrantFiled: April 16, 2002Date of Patent: April 22, 2008Assignee: Nihon Nohyaku Co., LtdInventors: Kazuyuki Sakata, Masayuki Morimoto, Hiroshi Kodama, Tetsuyosi Nishimatsu
-
Publication number: 20080044468Abstract: The present invention relates to a method for the preparation of bioavailable dosage form of modafinil.Type: ApplicationFiled: July 24, 2003Publication date: February 21, 2008Inventors: Romi Barat Singh, Pananchukunnath Manoj Kumar, Vishnubhotla Nagaprasad, Sunilendu Bhshan Roy, Rajiv Malik